Tracers / [177Lu]Lu-PEG-(DOTA)1(ACUPA)3
[177Lu]Lu-PEG-(DOTA)1(ACUPA)3
Also written as [Lu-177]PEG-(DOTA)1(ACUPA)3
- Radionuclide
- Lu-177 t½ 9584.6 min
- Modality
- Therapy
- Production route
- —
- Stage
- Reported once
- Syntheses indexed
- 1
What it is
- Compound class
- PSMA-targeted StarPEG nanocarrier with DOTA chelator and ACUPA PSMA-targeting ligands
- Target / mechanism
- PSMA (prostate-specific membrane antigen) targeting via ACUPA ligand PMID 38700450
- Clinical application
- Imaging and therapy of prostate cancer PMID 38700450
- Theranostic pair
- —
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| Manual synthesis | — | SPE | 91.8-99.2% | — | PEG-(DOTA)1(ACUPA)3 | 38700450 2024 Adv Healthc Mater StarPEG nanocarrier in water was added to a solution of 10 mM NH4OAc containing 10 vol% of ascorbic acid (20 mg/mL) and 177LuCl4 in a ratio of 0.37 MBq/μg of nanocarriers were mixed to it. — improved isolated yield (91.8-99.2%) and molar activity (14.6-15.8 MBq/nmol) were obtained for [177Lu]PEG-(DOTA)1(ACUPA)3 |
Need this precursor?We can point you to suppliers for [177Lu]Lu-PEG-(DOTA)1(ACUPA)3, or handle the enquiry for you.
Get in touchNotes
Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 38700450. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 38700450: 'PEG-(DOTA)1(ACUPA)3 (Yield 91%, 150 mg)'.